United Therapeutics (NASDAQ:UTHR) Earns “Buy” Rating from HC Wainwright

United Therapeutics (NASDAQ:UTHR)‘s stock had its “buy” rating reaffirmed by equities researchers at HC Wainwright in a research report issued to clients and investors on Thursday, Benzinga reports. They currently have a $300.00 price target on the biotechnology company’s stock. HC Wainwright’s price target suggests a potential upside of 14.33% from the stock’s previous close.

A number of other research analysts have also recently commented on the company. SVB Leerink started coverage on United Therapeutics in a research note on Monday, February 5th. They issued an “outperform” rating and a $330.00 target price on the stock. Leerink Partnrs reissued an “outperform” rating on shares of United Therapeutics in a report on Monday, February 5th. Wedbush reaffirmed an “outperform” rating and issued a $308.00 target price on shares of United Therapeutics in a research note on Thursday, February 22nd. Wells Fargo & Company increased their price target on shares of United Therapeutics from $309.00 to $325.00 and gave the company an “overweight” rating in a research report on Thursday, March 7th. Finally, The Goldman Sachs Group upgraded shares of United Therapeutics from a “sell” rating to a “neutral” rating and boosted their price objective for the stock from $213.00 to $215.00 in a report on Monday, February 12th. One investment analyst has rated the stock with a hold rating and ten have given a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $308.78.

United Therapeutics Price Performance

Shares of UTHR traded up $4.27 during trading hours on Thursday, reaching $262.40. 779,523 shares of the company’s stock traded hands, compared to its average volume of 541,180. The company has a current ratio of 3.77, a quick ratio of 4.28 and a debt-to-equity ratio of 0.04. The firm’s 50 day simple moving average is $236.86 and its 200-day simple moving average is $229.40. The stock has a market cap of $11.64 billion, a PE ratio of 12.41 and a beta of 0.54. United Therapeutics has a 12 month low of $204.44 and a 12 month high of $262.51.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings results on Wednesday, May 1st. The biotechnology company reported $6.17 EPS for the quarter, topping analysts’ consensus estimates of $5.63 by $0.54. The business had revenue of $677.70 million during the quarter, compared to analysts’ expectations of $620.31 million. United Therapeutics had a net margin of 42.05% and a return on equity of 18.72%. The business’s quarterly revenue was up 33.7% compared to the same quarter last year. During the same quarter in the previous year, the company earned $4.86 EPS. Equities analysts expect that United Therapeutics will post 23.75 EPS for the current year.

Insider Buying and Selling at United Therapeutics

In other United Therapeutics news, Director Christopher Patusky sold 1,680 shares of the business’s stock in a transaction dated Friday, February 23rd. The shares were sold at an average price of $224.00, for a total value of $376,320.00. Following the transaction, the director now owns 4 shares in the company, valued at $896. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In other news, CEO Martine A. Rothblatt sold 15,000 shares of the firm’s stock in a transaction dated Tuesday, March 19th. The shares were sold at an average price of $236.59, for a total value of $3,548,850.00. Following the completion of the sale, the chief executive officer now directly owns 130 shares of the company’s stock, valued at approximately $30,756.70. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Christopher Patusky sold 1,680 shares of the business’s stock in a transaction dated Friday, February 23rd. The shares were sold at an average price of $224.00, for a total transaction of $376,320.00. Following the transaction, the director now owns 4 shares in the company, valued at approximately $896. The disclosure for this sale can be found here. Insiders sold 141,790 shares of company stock valued at $33,572,685 in the last quarter. Company insiders own 12.50% of the company’s stock.

Institutional Trading of United Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the stock. TFB Advisors LLC lifted its stake in shares of United Therapeutics by 88.5% in the 1st quarter. TFB Advisors LLC now owns 1,909 shares of the biotechnology company’s stock valued at $487,000 after purchasing an additional 896 shares during the period. Mediolanum International Funds Ltd bought a new position in United Therapeutics in the first quarter worth $1,259,000. BI Asset Management Fondsmaeglerselskab A S lifted its position in United Therapeutics by 37.5% during the first quarter. BI Asset Management Fondsmaeglerselskab A S now owns 24,573 shares of the biotechnology company’s stock valued at $5,645,000 after buying an additional 6,708 shares during the period. Central Pacific Bank Trust Division bought a new stake in shares of United Therapeutics during the 1st quarter valued at $131,000. Finally, Daiwa Securities Group Inc. grew its position in shares of United Therapeutics by 15.2% in the 1st quarter. Daiwa Securities Group Inc. now owns 3,677 shares of the biotechnology company’s stock worth $845,000 after buying an additional 485 shares during the period. 94.08% of the stock is currently owned by hedge funds and other institutional investors.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.